Grifols (GRFS) Cost of Revenue (2010 - 2020)
Grifols' (GRFS) quarterly Cost of Revenue came in at $775.1 million in Q1 2020, up 8.46% YoY from $714.6 million in Q2 2019, and down 65.08% on a QoQ basis from $2.2 billion in Q4 2019.
Grifols (GRFS) Cost of Revenue (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Cost of Revenue data on file, last reported at $775.1 million in Q1 2020.
- Quarterly Cost of Revenue rose 8.46% year-over-year to $775.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $5.7 billion (up 40.75% YoY) and the FY2025 annual result came in at $5.4 billion, up 15.02% from the prior year.
- Cost of Revenue fell to $775.1 million in Q1 2020, from $2.2 billion in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $2.2 billion in Q4 2019 to a low of $553.8 million in Q1 2017.
- A 5-year average of $995.6 million and a median of $674.0 million in 2018 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2016 — Cost of Revenue climbed 3.94% — and 2017, when it surged 195.8%.
- Tracing GRFS's Cost of Revenue over 5 years: stood at $643.1 million in 2016, then jumped by 195.8% to $1.9 billion in 2017, then advanced by 3.94% to $2.0 billion in 2018, then rose by 12.25% to $2.2 billion in 2019, then sank by 65.08% to $775.1 million in 2020.
- The last three Cost of Revenue figures came in at $775.1 million (Q1 2020), $2.2 billion (Q4 2019), and $714.6 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.05 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 4.29 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.40 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.71 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.52 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.81 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.58 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.04 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 775.06 Mn |
| Mar 31, 2020 | 775.06 Mn |
| Dec 31, 2019 | 2.22 Bn |
| Dec 31, 2019 | 2.22 Bn |
| Mar 31, 2019 | 714.63 Mn |
| Mar 31, 2019 | 714.63 Mn |
| Dec 31, 2018 | 1.98 Bn |
| Dec 31, 2018 | 1.98 Bn |
| Jun 30, 2018 | 691.82 Mn |
| Jun 30, 2018 | 691.82 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Mar 31, 2018 | 656.26 Mn |
| Dec 31, 2017 | 1.90 Bn |
| Dec 31, 2017 | 1.90 Bn |
| Jun 30, 2017 | 626.15 Mn |
| Jun 30, 2017 | 626.15 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Mar 31, 2017 | 553.78 Mn |
| Dec 31, 2016 | 643.10 Mn |
| Dec 31, 2016 | 643.10 Mn |